

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 65043

Title: Adjuvant therapy for lung neuroendocrine neoplasms

Reviewer's code: 05778529

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Poland

Author's Country/Territory: United States

Manuscript submission date: 2021-02-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-26 09:12

Reviewer performed review: 2021-05-05 09:55

Review time: 9 Days

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Dear Authors, The manuscript titled: “Adjuvant therapy for neuroendocrine neoplasms of the lung” by Robert A. Ramirez et al. aimed to discuss the possible use and need of adjuvant therapy in patients with lung NENs. The authors have come to the conclusion, that unlike non-small cell lung cancer where adjuvant therapy is well established, adjuvant therapy for NENs of the lung, specially for typical and atypical carcinoids is less accepted and further prospective studies are warranted. The study is generally well designed, well presented and the results are potentially of a certain interest. The main idea of the manuscript gives some approach to the discussion of possible use or need of adjuvant therapy in low grade lung NENs. It's in fact still unresolved problem, because many studies show even detrimental effect for those patients. There are however some issues that should be addressed. 1. Abstract: I do not see the abstract. Is it not required? 2. Introduction: To clarify the issue, it would be worth to include actual pathological classification of lung NEN (TC, AC, LCNEC, SCLC) with grading and some with staging 3. Adjuvant treatment in TC and AC section: When you mention about radiation therapy, chemotherapy or chemoradiation therapy, you should explain in any place what kind of each therapy was used (e.g. study of Wegner et. al. 2019) 4. Conclusion are in point and well presented. 5. Table 1: As above – what kind of chemotherapy is recommended in ENETS, NCCN and ESMO guidelines? Also as above – staging classification you should place in the introduction. 6. There are several misspelling and grammar errors. Please go through the paper thoroughly. 7. Finally, considering the whole article, your manuscript might be accepted for publication in the WJCO pending changes mentioned above.